TACE术中应用吉西他滨对原发性肝癌疗效及血清甲胎蛋白的影响

Efficacy of Gemcitabine Application during TACE in Treatment of Patients with Primary Hepatocellular Carcinoma and Its Effect on Serum Alpha-fetoprotein

目的分析肝动脉化疗栓塞术(TACE)中应用吉西他滨治疗原发性肝癌(PHC)的疗效及安全性。方法回顾性分析2015年3月—2016年3月80例PHC患者的临床资料,按照TACE使用药物的不同分为研究组和对照组,每组40例。研究组给予吉西他滨为主的TACE方案,对照组给予洛铂为主的TACE方案。分别比较2组的临床疗效、血清甲胎蛋白(AFP)、毒副反应及预后情况。结果 2组的客观有效率、1年生存率和毒副反应发生情况比较差异无统计学意义(P>0.05)。研究组的疾病控制率和2年生存率明显高于对照组(P<0.05)。治疗后,2组血清AFP水平明显低于治疗前,且研究组明显低于对照组(P<0.05)。结论 TACE中应用吉西他滨对PHC的临床疗效肯定,可有效降低患者血清AFP水平,提高生存率,且不增加治疗后的毒副反应。

Objective To analyze efficacy and safety of Gemcitabine application during transcatheter arterial chemoembolization (TACE) in treatment of patients with primary hepatocellular carcinoma (PHC). Methods Clinical data of 80 patients with PHC during March 2015 and March 2016 was retrospectively analyzed, and the patients were divided into study group and control group ( n =40 for each group) according to different drug uses for TACE. Study group was given Gemcitabine-based TACE, while control group was given Lobaplatin-based TACE. Clinical efficacy, serum alpha-fetoprotein (AFP) level, toxicity and side reactions and prognosis were compared in two groups. Results There were no significant differences in objective effective rate, 1-year survival rate and incidence rate of toxic and side reactions between two groups ( P >0.05). Disease control rate and 2-year survival rate in study group were significantly higher than those in control group ( P <0.05). After treatment, levels of serum AFP were significantly lower than those before treatment in two groups, and the level in study group was significantly lower than that in control group ( P <0.05). Conclusion Gemcitabine application during TACE for patients with PHC may achieve definedly clinical efficacy, and it may effectively reduce level of serum AFP and improve survival rate without increasing toxicity and side reactions after treatment.